/term/bs-other-liabilities-bank/LTS:0A8E Xeris Biopharma Holdings (LTS:0A8E) Other Liabilities for B
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Other Liabilities for Banks

Xeris Biopharma Holdings (LTS:0A8E) Other Liabilities for Banks


View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Other Liabilities for Banks?

Other Liabilities (Bank) only applies to banks.

Xeris Biopharma Holdings (LTS:0A8E) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Other Liabilities for Banks
Comparable Companies
YMAB DRTS CMPX CELC ACIU IGMS NUVB ARQT ZURA OVID OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
XERS:USA 2B30:Germany
Address
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Website
https://www.xerispharma.com
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.